ABSTRACT
The rate of symptomatic improvement of visual symptoms associated with hematogenous
metastases to the sella and pituitary was evaluated retrospectively in seven patients
(five men, two women; mean age, 52.3 years) with primarily visual symptoms (diplopia
alone in three, diplopia with blurred vision in one, blurred vision alone in one,
loss of peripheral vision in one, and unilateral complete blindness in one). Symptom
duration ranged from 0.5 to 2 months. The primary diseases were non-small cell lung
cancer in two patients, renal cell carcinoma in two patients, prostate cancer in two
patients, and medullary thyroid carcinoma in one patient. All patients had widespread
metastatic disease. Three patients had a suprasellar tumoral component. One patient
had a clival extension, and one patient had extension into the cavernous sinus. All
underwent trans-sphenoidal surgery to correct visual symptoms. Gross total resection
was achieved in three patients. Subtotal resections and a partial resection were performed
in three patients and one patient, respectively. Surgical blood loss averaged 282
mL. One patient died from sepsis. Five patients developed complications (cerebrospinal
fluid leakage in three, diabetes insipidus in two, anterior pituitary dysfunction
in two, and colitis in one). At a mean follow-up of 15 months, three patients were
alive. Visual symptoms improved in five patients and were unchanged in two. Trans-sphenoidal
surgery helped improve visual symptoms in most patients. The morbidity rate was high
and likely related to the locally destructive and extensive nature of the lesions
in overall morbid patients with widespread metastatic disease. Unless nonoperative
measures can provide equal results, however, this approach provides reasonable palliation.
KEYWORDS
Metastatic disease - pituitary gland - transnasal - sublabial - vision - sellar mass
REFERENCES
- 1
Kovacs K.
Metastatic cancer of the pituitary gland.
Oncology.
1973;
27
533-542
- 2
Abrams H L, Spiro R, Goldstein N.
Metastases in carcinoma: analysis of 1000 autopsied cases.
Cancer.
1950;
3
74-85
- 3
Heshmati H M, Scheithauer B W, Young Jr W F.
Metastases to the pituitary gland.
Endocrinologist.
2002;
12
45-49
- 4
Teears R J, Silverman E M.
Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland.
Cancer.
1975;
36
216-220
- 5
Komninos J, Vlassopoulou V, Protopapa D et al..
Tumors metastatic to the pituitary gland: case report and literature review.
J Clin Endocrinol Metab.
2004;
89
574-580
- 6
Juneau P, Schoene W C, Black P.
Malignant tumors in the pituitary gland.
Arch Neurol.
1992;
49
555-558
- 7
Landolt A M.
Comments on: Nelson PB, Robinson AG, Martinez AJ. Metastatic tumor of the pituitary
gland.
Neurosurgery.
1987;
21
941-944
- 8
McCormick P C, Post K D, Kandji A D, Hays A P.
Metastatic carcinoma to the pituitary gland.
Br J Neurosurg.
1989;
3
71-79
- 9
Gsponer J, De Tribolet N, Deruaz J P et al..
Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar
masses: retrospective analysis of 353 patients.
Medicine (Baltimore).
1999;
78
236-269
- 10
Branch Jr C L, Laws Jr E R.
Metastatic tumors of the sella turcica masquerading as primary pituitary tumors.
J Clin Endocrinol Metab.
1987;
65
469-474
- 11
Max M B, Deck M D, Rottenberg D A.
Pituitary metastasis: incidence in cancer patients and clinical differentiation from
pituitary adenoma.
Neurology.
1981;
31
998-1002
- 12
Houck W A, Olson K B, Horton J.
Clinical features of tumor metastasis to the pituitary.
Cancer.
1970;
26
656-659
- 13
Sioutos P, Yen V, Arbit E.
Pituitary gland metastases.
Ann Surg Oncol.
1996;
3
94-99
- 14
Morita A, Meyer F B, Laws Jr E R.
Symptomatic pituitary metastases.
J Neurosurg.
1998;
89
69-73
- 15
Fassett D R, Couldwell W T.
Metastases to the pituitary gland.
Neurosurg Focus.
2004;
16
E8
- 16
McCutcheon I E, Waguespack S G, Fuller G N, Couldwell W T.
Metastatic melanoma to the pituitary gland.
Can J Neurol Sci.
2007;
34
322-327
- 17
McCutcheon I E, Kitagawa R H, Sherman S I, Bruner J M.
Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report.
Neurosurgery.
2001;
48
1161-1165
- 18
Marin F, Kovacs K T, Scheithauer B W, Young Jr W F.
The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical
study of 125 cases.
Mayo Clin Proc.
1992;
67
949-956
- 19
Post K D, McCormick P C, Hays A P, Kandji A G.
Metastatic carcinoma to pituitary adenoma: report of two cases.
Surg Neurol.
1988;
30
286-292
- 20
Weber J, Gassel A M, Hoch A, Spring A.
Concomitant renal cell carcinoma with pituitary adenoma.
Acta Neurochir (Wien).
2003;
145
227-231
- 21
Molinatti P A, Scheithauer B W, Randall R V, Laws Jr E R.
Metastasis to pituitary adenoma.
Arch Pathol Lab Med.
1985;
109
287-289
- 22
McDermott R S, Anderson P R, Greenberg R E, Milestone B N, Hudes G R.
Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features
and treatment outcomes.
Cancer.
2004;
101
1639-1643
- 23
Murata Y, Ogawa Y, Yokoe I et al..
Pituitary stalk metastasis from breast cancer treated with systemic chemotherapy.
Oncol Rep.
2003;
10
1973-1975
- 24
Patel N, Teh B S, Powell S, Lu H H, Amato R, Butler E B.
Rare case of metastatic prostate adenocarcinoma to the pituitary.
Urology.
2003;
62
352
- 25
Iwai Y, Yamanaka K, Honda Y, Matsusaka Y.
Radiosurgery for pituitary metastases.
Neurol Med Chir (Tokyo).
2004;
44
112-116
- 26
Piedra M P, Brown P D, Carpenter P C, Link M J.
Resolution of diabetes insipidus following gamma knife surgery for a solitary metastasis
to the pituitary stalk: case report.
J Neurosurg.
2004;
101
1053-1056
- 27
Losa M, Grasso M, Giugni E, Mortini P, Acerno S, Giovanelli M.
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the
lesion and clinical improvement with medical treatment.
Prostate.
1997;
32
241-245
- 28
Kattah J C, Silgals R M, Manz H, Toro J G, Dritschilo A, Smith F P.
Presentation and management of parasellar and suprasellar metastatic mass lesions.
J Neurol Neurosurg Psychiatry.
1985;
48
44-49
Ian E McCutcheonM.D.
Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center
PO Box 301402, Unit 442, Houston, TX 77230-1402
Email: imccutch@mdanderson.org